Menu
Close
Olpha is open for participation in co-development projects, including the development and research of new pharmaceutical products.
Contact us
Development of products with immediate release (tablet & capsule) modified release (tablet & capsule), Immediate & modified release coating, sugar coating
Direct pressing of tablets and capsules
Direct mixing of sachets
Dry granulation/sealing for tablets and capsules
Wet granulation in a high-speed mixer for tablets and capsules
Wet granulation of tablets and capsules in a pseudo-fluidized bed
Wet granulation in a Sigma blade mixer
Filling powders into sachets
production
production capacity for tablets and capsules per year
investment in
R&D in 2022
investment in new generic medicine portfolio in 2024
With a team of 800+ professional employees and 50+ years of experience, Olpha is an expert in the development and production of finished dosage forms and active pharmaceutical ingredients and intermediates in a vast range of therapeutic areas.
Our production plant is located in the European Union, in Latvia, and has a 480,000 square meter area with easy access to the highway and airport. Our laboratories are equipped with modern, industry standard instruments.
We approach each client’s needs and evaluate each cooperation on an individual level. We believe the best way of collaborating is finding the most suitable solution for any need together.
Olpha is develops generics as well as APIs and stands out with the full-cycle production offering.
Olpha ensures consistent product availability to meet the market demand.
Efficient production processes, lower labour costs and regionally developed logistics result in greater cost efficiency.
Olpha holds its production to the highest industry quality standards. See more information on quality control and assurance on our Product governance page.
Our processes include effective sustainability measures, ensuring that our business processes are good for people and the planet. See more information on our Sustainability section.